Assessment of IgRT among patients diagnosed with CLL and NHL receiving 1 or more IgRT during follow-up
| Characteristics . | CLL (n = 259) . | NHL (n = 623) . |
|---|---|---|
| Year of first IgRT, n (%) | ||
| 2010-2015 | 14 (12.5) | 18 (6.1) |
| 2016-2020 | 59 (52.7) | 166 (56.7) |
| 2021-2023 | 39 (34.8) | 109 (37.2) |
| Number of IgRT | ||
| Mean ± SD | 5.5 ± 8.8 | 4.9 ± 10.0 |
| Median (IQR) | 2.0 (1.0-4.0) | 2.0 (1.0-4.0) |
| Number of IgRT, n (%) | (1, 47) | (1, 101) |
| 1 | 112 (43.2) | 293 (47.0) |
| 2 | 40 (15.4) | 112 (18.0) |
| 3 | 25 (9.7) | 47 (7.5) |
| 4 | 21 (8.1) | 40 (6.4) |
| 5 | 8 (3.1) | 16 (2.6) |
| 6 | 8 (3.1) | 17 (2.7) |
| 7 | 1 (0.4) | 13 (2.1) |
| ≥8 | 44 (17.0) | 85 (13.6) |
| Patients with at least 1 IgG test, n (%) | 244 (94.2) | 584 (93.7) |
| Serum IgG level closest to IgRT initiation (mg/dL)∗, n (%) | ||
| <200 | 39 (16.0) | 93 (15.9) |
| ≥200 to <400 | 80 (32.8) | 238 (40.8) |
| ≥400 to <500 | 29 (11.9) | 54 (9.2) |
| ≥500 to <600 | 34 (13.9) | 37 (6.3) |
| ≥600 | 62 (25.4) | 162 (27.7) |
| Patients with at least 1 IgG test before IgRT initiation, n (%) | 215 (83.0) | 516 (82.8) |
| Time from last IgG test to IgRT initiation†, mo | ||
| Mean ± SD | 6.5 ± 16.3 | 2.5 ± 9.9 |
| Median (IQR) | 0.6 (0.1-3.5) | 0.2 (0.1-1.0) |
| Serum IgG level, mg/dL | ||
| Mean ± SD | 462.0 ± 359.0 | 455.2 ± 415.0 |
| Median (IQR) | 369.0 (255.0-545.0) | 356.5 (248.0-502.5) |
| Patients with ≥2 IgRT, n (%) | 147 (56.8) | 330 (53.0) |
| Time from first IgRT to subsequent IgG testing, mo | ||
| Mean ± SD | 6.3 ± 10.6 | 3.7 ± 7.8 |
| Median (IQR) | 1.6 (0.7-7.0) | 1.0 (0.3-3.0) |
| Characteristics . | CLL (n = 259) . | NHL (n = 623) . |
|---|---|---|
| Year of first IgRT, n (%) | ||
| 2010-2015 | 14 (12.5) | 18 (6.1) |
| 2016-2020 | 59 (52.7) | 166 (56.7) |
| 2021-2023 | 39 (34.8) | 109 (37.2) |
| Number of IgRT | ||
| Mean ± SD | 5.5 ± 8.8 | 4.9 ± 10.0 |
| Median (IQR) | 2.0 (1.0-4.0) | 2.0 (1.0-4.0) |
| Number of IgRT, n (%) | (1, 47) | (1, 101) |
| 1 | 112 (43.2) | 293 (47.0) |
| 2 | 40 (15.4) | 112 (18.0) |
| 3 | 25 (9.7) | 47 (7.5) |
| 4 | 21 (8.1) | 40 (6.4) |
| 5 | 8 (3.1) | 16 (2.6) |
| 6 | 8 (3.1) | 17 (2.7) |
| 7 | 1 (0.4) | 13 (2.1) |
| ≥8 | 44 (17.0) | 85 (13.6) |
| Patients with at least 1 IgG test, n (%) | 244 (94.2) | 584 (93.7) |
| Serum IgG level closest to IgRT initiation (mg/dL)∗, n (%) | ||
| <200 | 39 (16.0) | 93 (15.9) |
| ≥200 to <400 | 80 (32.8) | 238 (40.8) |
| ≥400 to <500 | 29 (11.9) | 54 (9.2) |
| ≥500 to <600 | 34 (13.9) | 37 (6.3) |
| ≥600 | 62 (25.4) | 162 (27.7) |
| Patients with at least 1 IgG test before IgRT initiation, n (%) | 215 (83.0) | 516 (82.8) |
| Time from last IgG test to IgRT initiation†, mo | ||
| Mean ± SD | 6.5 ± 16.3 | 2.5 ± 9.9 |
| Median (IQR) | 0.6 (0.1-3.5) | 0.2 (0.1-1.0) |
| Serum IgG level, mg/dL | ||
| Mean ± SD | 462.0 ± 359.0 | 455.2 ± 415.0 |
| Median (IQR) | 369.0 (255.0-545.0) | 356.5 (248.0-502.5) |
| Patients with ≥2 IgRT, n (%) | 147 (56.8) | 330 (53.0) |
| Time from first IgRT to subsequent IgG testing, mo | ||
| Mean ± SD | 6.3 ± 10.6 | 3.7 ± 7.8 |
| Median (IQR) | 1.6 (0.7-7.0) | 1.0 (0.3-3.0) |